The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July...

SHINE Technologies, a next-generation fusion company, will showcase FLARE™, the world's most powerful continuous fusion neutron system, at the IEEE Nuclear & Space Radiation Effects and at the...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced the launch of a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the #1 prescribed vesicular monoamine transporter 2 (VMAT2)...

Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory diseases,...

Cytonics Corporation, a private biotechnology company developing biologic therapies for musculoskeletal ailments, announced initiation of enrollment for its Phase 1 clinical study of...

Oticon Medical announced the U.S. Food and Drug Administration (FDA) clearance of its first active transcutaneous bone conduction hearing system, the Sentio System. Sentio System delivers the proven...

Tiba Biotech LLC, a Cambridge-based preclinical biopharmaceutical company, announces its new partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the...

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. a clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies for achieving functional cure in chronic...

BioArctic AB's partner Eisai announced that the Department of Health in Hong Kong has approved Leqembi® (brand name in Hong Kong, generic name: lecanemab) for...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the...

PharmAbcine, Inc. a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today the decision to advance PMC-403, its candidate treatment for...

Kedrion Biopharma Inc. announced that it has established the framework for a long-term agreement with Biotest AG for the full commercialization and distribution of the immunoglobulin therapy...